Biocon's subsidiary Biocon Biologics has acquired R&D capital assets for a 60,000 square foot bench-to-pilot scale biologics research facility at TICEL Bio Park in Chennai, India from Pfizer Healthcare India.
"The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide," said Christiane Hamacher, CEO of Biocon Biologics. "This investment will allow us to fast-forward development of our biosimilars from lab to pilot scale. R&D is at the core of what we do and I believe this facility will enable us to pursue breakthrough innovation in pursuit of providing affordable access to high quality biosimilars and inclusive healthcare solutions aimed at transforming patient lives globally."
The facility will house an early stage research and innovation center including a pilot scale R&D Unit, equipped with cell line development, drug substance process development from bench scale to 400-liter scale bioreactors, drug product formulation laboratories and analytical R&D laboratories. The facility is expected to be operational in a few months post qualification and will house over 250 scientists.
Currently, Biocon Biologics has a 200,000 square foot R&D center at Biocon Park, Bengaluru, India. The company has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own.
Read the full Biocon release